Related Experiment Video

Updated: Nov 2, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.9K

Checkpoint inhibitors in metastatic papillary renal cell carcinoma

M de Vries-Brilland1, D F McDermott2, C Suárez3

  • 1Department of Medical Oncology, Integrated Centers of Oncology (ICO) Paul Papin, Angers, France.

Cancer Treatment Reviews
|June 10, 2021
PubMed

Insights

Papillary renal cell carcinoma (pRCC) treatments are evolving. While immune checkpoint inhibitors show limited efficacy alone, combinations with tyrosine-kinase inhibitors offer promising results for metastatic pRCC.

Area of Science:

  • Oncology
  • Immunotherapy
  • Renal Cell Carcinoma Research

Background:

  • Papillary renal cell carcinoma (pRCC) is a common and aggressive subtype of non-clear cell renal cell carcinoma (nccRCC).
  • Current treatments for metastatic pRCC (mpRCC), including antiangiogenics and mTOR inhibitors, demonstrate limited efficacy.
  • The development of immune checkpoint inhibitors (ICIs) presents a new therapeutic avenue for mpRCC.

Purpose of the Study:

  • To review early activity data of ICIs in mpRCC.
  • To explore potential future therapeutic strategies involving ICIs in monotherapy or combination.
  • To discuss the role of immune checkpoints and cellular infiltrates in pRCC immunogenicity.

Main Methods:

  • Review of retrospective and prospective data on ICI efficacy in mpRCC.
  • Analysis of immune checkpoint expression (e.g., PD-L1) and immune cell infiltration in pRCC.
  • Evaluation of combination therapies, particularly with tyrosine-kinase inhibitors (TKIs).

Main Results:

  • ICI monotherapy shows limited efficacy in mpRCC.
  • Combination therapies, especially with anti-MET TKIs, demonstrate promising response rates.
  • The molecular and immune landscape of pRCC requires further elucidation.

Conclusions:

  • ICI monotherapy has limited effectiveness in papillary renal cell carcinoma.
  • Combinations of ICIs with TKIs, particularly anti-MET inhibitors, show potential for treating metastatic pRCC.
  • Further research and biomarker-driven clinical trials are essential for advancing pRCC treatment.
Keywords:
Checkpoint inhibitorsImmunotherapyMetastatic papillary renal-cell cancer

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.8K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

744

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
299
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
317